Hematological Neoplasms

Based on these data, a second-generation bispecific BC19 CAR targeting BCMA and CD19 was designed. This trial reports the preclinical results of BC19 CAR-T cells and the outcomes of R/R MM patients treated in the phase I/II trial.

During this EBMT meeting, Professor Qiu Lugui’s team reported the latest subgroup analysis results from the FUMANBA-1 study (Abstract No. OS10-04) on B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (CAR-T) cell therapy for relapsed or refractory multiple myeloma (RRMM).

Following the global launch of the first approved TIL cell therapy, lifileucel, the second CAR-T product in China for the treatment of multiple myeloma, Zevorcabtagene Autoleucel (赛恺泽), has finally received approval from the National Medical Products Administration (NMPA) for its new drug application to treat adult patients with relapsed or refractory multiple myeloma.

In August 2023, the Department of Hematology at Nanfang Hospital, Southern Medical University, admitted a case of MM. The patient had relapsed after multiple lines of prior treatment and progressed to refractory MM with extramedullary disease.

Recently, Legend Biotech (NASDAQ: LEGN) announced in Somerset, New Jersey, that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (Ciltacabtagene Autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), and are refractory to lenalidomide1.

In this dire situation, after a comprehensive evaluation by Professors Jin Jie and Yang Min’s team at the First Affiliated Hospital of Zhejiang University School of Medicine, they determined that CAR-T cell therapy was Mr.

When All Treatment Options Were Exhausted, Cancer Rapidly Progressed, and the Doctor Regretfully Said That Ms. M Did Not Respond to Any Medication.